Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemborexant effects on AD biomarkers
NCT05728736Phase 2Withdrawn
- Sponsor
- Brendan Lucey
- Start
- Mar 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lemborexant in Alzheimer's disease (AD), sponsored by Brendan Lucey. Planned start Mar 2023; status: withdrawn.
02
Drugs
lemborexant
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05728736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05728736.